Table 1. Baseline patient characteristics and findings.
| Variable | Case group ( n = 13) |
Control group ( n = 13) |
p -Value |
|---|---|---|---|
| Male, n (%) | 5 (38) | 9 (69) | 0.238 |
| Age (mo), median (IQR) | 6 (2–11) | 10 (2–23) | 0.455 |
| Pediatric Index of Mortality 2, median (IQR) | 4.4 (1.1–5.8) | 3.6 (1.0–5.2) | 0.455 |
| PaO 2 /FIO2 ratio, median (IQR) | 168 (135–266) | 184 (127–203) | 0.898 |
| PaO 2 /FIO2 ratio < 200, n (%) | 8 (62) | 9 (69) | 1.000 |
| Oxygenation index, median (IQR) | 6.7 (4.8–9.1) | 5.3 (3.7–10.0) | 0.579 |
| pH, median (IQR) | 7.357 (7.289–7.409) | 7.299 (7.253–7.309) | 0.076 |
| PaCO 2 (mm Hg), median (IQR) | 47 (41–60) | 55 (51–64) | 0.330 |
| Peak inspiratory pressure (cmH 2 O), median (IQR) | 25 (24–26) | 21 (18–24) | 0.058 |
| Indication for endotracheal intubation, n (%) | |||
| Status asthmaticus | 2 (15) | 3 (23) | 0.881 |
| Bacterial or viral pneumonia | 10 (77) | 9 (69) | |
| Bronchitis | 1 (8) | 1 (8) | |
| Duration of mechanical ventilation, median (IQR) | 3 (3–4) | 1 (1–2) | 0.019 |
| Fluid balance (%), median (IQR) | |||
| 24 h after intubation | 2.1 (1.8–6.4) | 3.1 (1.5–5.5) | 0.798 |
| 48 h after intubation | −0.7 (−2.4 to 2.0) | 0.3 (−0.7 to 1.7) | 0.427 |
| Dosage of furosemide | |||
| Maximal dose (mg/kg/d), median (IQR) | 2.0 (2–2) | ||
| Route of administration, n (%) | |||
| Enteral | 4 (30) | ||
| Intermittent intravenous bolus | 1 (8) | ||
| Continuous intravenous infusion | 8 (62) | ||
| Duration of furosemide (d), median (IQR) | 2 (2–3) | ||
| Adverse event, n (%) | |||
| Death before discharge from hospital | 0 | 0 | |
| Pneumothorax | 0 | 0 | |
| Ventilator-associated pneumonia | 0 | 0 | |
| Difficult extubation | 0 | 0 | |
| Tracheostomy | 0 | 0 | |
| Unexpected delayed extubation | 0 | 0 | |
| Severe electrolyte derangement | 0 | 0 | |
Abbreviations: FIO2, fraction of inspired oxygen IQR, interquartile range; PaCO 2 , partial pressure of carbon dioxide; PaO 2 , partial pressure of oxygen.